Company Encyclopedia
View More
name
Rafael-B
RFL.US
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
4.514 T
RFL.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking89/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-34.57%E
    • Profit Margin-3328.24%E
    • Gross Margin85.39%A
  • Growth ScoreA
    • Revenue YoY43.96%A
    • Net Profit YoY11.30%C
    • Total Assets YoY17.84%A
    • Net Assets YoY14.04%A
  • Cash ScoreB
    • Cash Flow Margin-3.00%D
    • OCF YoY43.96%A
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio13.79%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Rafael-B | 10-K: FY2025 Revenue: USD 917 K

    LB filings·
    US
    RFL
    -2.40%
    LB filings·
    US
    RFL
    -2.40%

    Rafael-B | 8-K: FY2025 Q4 Revenue: USD 350 K

    LB filings·
    US
    RFL
    -2.40%
    LB filings·
    US
    RFL
    -2.40%

    Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results | RFL Stock News

    Rafael Holdings, Inc. reported its financial results for Q4 and full fiscal year 2025, ending July 31, 2025. The company recorded a net loss of $12.1 million for Q4 and $30.5 million for the full year. The increase in losses is attributed to the consolidation of Cyclo Therapeutics' expenses following its acquisition. R&D expenses rose significantly due to this acquisition. The company also closed a $25 million rights offering to enhance its financial position. CEO Howard Jonas highlighted the progress of the Phase 3 TransportNPC™ study for Niemann-Pick Disease Type C1.

    StockTitan·
    US
    RFL
    -2.40%
    StockTitan·
    US
    RFL
    -2.40%

    U.S. stock market update: Rafael-B down 17.28%

    Rafael-B fell 17.28%; Eli Lilly fell 1.26%, with a trading volume of USD 1.919 billion; Johnson & Johnson rose 1.04%, with a trading volume of USD 1.043 billion; Pfizer fell 0.95%, with a trading volume of USD 880 million; Novo Nordisk fell 0.83%, with a market value of USD 272.6 billion

    Tracking Unusual Activity·
    US
    RFL
    -2.40%
    Tracking Unusual Activity·
    US
    RFL
    -2.40%

    Rafael (NYSE:RFL) Shares Down 3.6% - Here's Why

    Rafael Holdings, Inc. (NYSE:RFL) shares fell 3.6% to $1.48 during mid-day trading, with a trading volume increase of 35%. The stock has a market cap of $51.76 million and a negative EPS of ($0.19). CEO Howard S. Jonas significantly increased his stake by purchasing over 13 million shares. Analysts have upgraded Rafael from a 'sell' to a 'hold' rating, but it remains off the list of top stock recommendations. Institutional investors hold 11.30% of the company.

    Market Beat·
    US
    RFL
    -2.40%
    Market Beat·
    US
    RFL
    -2.40%
    © 2025 Longbridge｜Disclaimer